Favorable treatment outcome in children with acute myeloid leukemia and Down syndrome.

Suppr

超能文献

作者信息

Kojima S, Kato K, Matsuyama T, Yoshikawa T, Horibe K

出版信息

Blood. 1993 Jun 1;81(11):3164.

PMID:8499650

Abstract

摘要

相似文献

Favorable treatment outcome in children with acute myeloid leukemia and Down syndrome.

Blood. 1993 Jun 1;81(11):3164.

Megakaryoblastic leukemia and Down's syndrome: a review.

Pediatr Hematol Oncol. 1987;4(3):211-30. doi: 10.3109/08880018709141272.

The treatment of children with acute megakaryoblastic leukemia who have Down syndrome.

J Pediatr Hematol Oncol. 1996 Feb;18(1):10-2. doi: 10.1097/00043426-199602000-00003.

Acute megakaryoblastic leukemia and clonal trisomy 21 in a phenotypically normal infant.

Blood. 1991 Jun 1;77(11):2542-3.

[Acute megakaryoblastic leukemia in early childhood; report of two cases].

Rinsho Ketsueki. 1988 Feb;29(2):214-20.

GATA1 mutations in patients with down syndrome and acute megakaryoblastic leukaemia do not always confer a good prognosis.

Pediatr Blood Cancer. 2009 Jul;53(1):108-11. doi: 10.1002/pbc.21983.

Acute megakaryoblastic leukemia associated with mosaic Down's syndrome.

Cancer. 1987 Nov 15;60(10):2515-20. doi: 10.1002/1097-0142(19871115)60:10<2515::aid-cncr2820601028>3.0.co;2-f.

Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group.

J Clin Oncol. 2007 Dec 1;25(34):5442-7. doi: 10.1200/JCO.2007.12.3687.

An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome.

Leukemia. 2000 May;14(5):786-91. doi: 10.1038/sj.leu.2401754.

Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia.

Blood. 1996 Apr 15;87(8):3395-403.

引用本文的文献

Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome.

Blood Adv. 2023 Nov 14;7(21):6532-6539. doi: 10.1182/bloodadvances.2022009381.

High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial.

Blood. 2021 Dec 9;138(23):2337-2346. doi: 10.1182/blood.2021012206.

Prognosis and management of acute myeloid leukemia in patients with Down syndrome.

Expert Rev Hematol. 2014 Dec;7(6):831-40. doi: 10.1586/17474086.2014.959923. Epub 2014 Sep 18.

Distinctive multidrug sensitivity and outcome of acute erythroblastic and megakaryoblastic leukemia in children with Down syndrome.

Int J Hematol. 2001 Dec;74(4):428-36. doi: 10.1007/BF02982087.

Malignancies in Down syndrome.

Indian J Pediatr. 1997 Nov-Dec;64(6):873-8. doi: 10.1007/BF02725515.

Improved outcome of acute myeloid leukaemia in Down's syndrome.

Arch Dis Child. 1999 Jul;81(1):32-7. doi: 10.1136/adc.81.1.32.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验